Fate Therapeutics, Inc.
FATE
$1.90
-$0.01-0.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.30M | 1.37M | 1.74M | 1.91M | 1.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.30M | 1.37M | 1.74M | 1.91M | 1.63M |
| Cost of Revenue | 24.70M | 9.50M | 25.84M | 3.82M | 29.14M |
| Gross Profit | -23.40M | -8.13M | -24.10M | -1.91M | -27.51M |
| SG&A Expenses | 9.60M | 25.50M | 10.64M | 11.45M | 13.77M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.30M | 34.99M | 36.48M | 38.88M | 42.91M |
| Operating Income | -33.00M | -33.62M | -34.74M | -36.97M | -41.28M |
| Income Before Tax | -31.21M | -32.37M | -32.25M | -34.07M | -37.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.21M | -32.37M | -32.25M | -34.07M | -37.62M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.21M | -32.37M | -32.25M | -34.07M | -37.62M |
| EBIT | -33.00M | -33.62M | -34.74M | -36.97M | -41.28M |
| EBITDA | -30.08M | -30.56M | -31.51M | -33.69M | -37.95M |
| EPS Basic | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 |
| Normalized Basic EPS | -0.16 | -0.16 | -0.17 | -0.18 | -0.20 |
| EPS Diluted | -0.26 | -0.27 | -0.27 | -0.29 | -0.32 |
| Normalized Diluted EPS | -0.16 | -0.16 | -0.17 | -0.18 | -0.20 |
| Average Basic Shares Outstanding | 120.03M | 119.25M | 119.00M | 118.53M | 118.38M |
| Average Diluted Shares Outstanding | 120.03M | 119.25M | 119.00M | 118.53M | 118.38M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |